Insights in Gynecologic Oncology
Open Access

The exact cause of vulva cancer is not always clear, but several risk factors have been identified, including human papillomavirus (HPV) infection, smoking, a weakened immune system, chronic skin conditions, and a history of precancerous lesions in the vulva. Early detection and diagnosis of vulva cancer are crucial for effective treatment. Treatment options typically include surgery to remove the cancerous tissue, radiation therapy, and chemotherapy, depending on the stage and type of cancer. It's essential for women to be aware of their bodies, undergo regular gynecological check-ups, and report any unusual symptoms to their healthcare providers promptly. Early intervention can significantly improve the prognosis and quality of life for those diagnosed with vulva cancer [1].

Here's a more in-depth discussion

Risk factors

• HPV infection: Human papillomavirus (HPV) infection is a significant risk factor for vulva cancer. HPV vaccines have been developed to protect against certain strains of the virus, potentially reducing the risk.

• Smoking: Smoking has been linked to an increased risk of vulva cancer. Quitting smoking can reduce this risk.

• Immunosuppression: Conditions or medications that weaken the immune system can increase susceptibility to vulva cancer.

• Chronic skin conditions: Conditions like lichen sclerosus and lichen planus can lead to chronic inflammation and may increase the risk.

• Age: Vulva cancer is more commonly diagnosed in older women, although it can affect women of all ages.

Symptoms and diagnosis

• Vulva cancer often presents with symptoms such as itching, pain, tenderness, or changes in the appearance of the vulvar skin.

• A healthcare provider will perform a physical examination, including a pelvic exam, to assess any abnormalities.

• A biopsy is typically required to confirm the diagnosis. This involves taking a small sample of tissue from the vulva for examination under a microscope.

Staging and treatment:

• Vulva cancer is staged to determine the extent of the disease and guide treatment decisions. Stages range from I (early) to IV (advanced).

Treatment options may include

1. Surgery: Surgical removal of the cancerous tissue is often the primary treatment. Depending on the stage and extent, this may involve a wide local excision or a more extensive procedure like a vulvectomy.

2. Radiation therapy: Radiation may be used before or after surgery, or as the primary treatment for advanced cases.

3. Chemotherapy: Chemotherapy can be used in combination with other treatments, especially for advanced or recurrent cases.

4. Immunotherapy: Emerging treatments like immunotherapy are being studied for vulva cancer [2].

Emotional and psychological impact

• A Diagnosis Of Vulva Cancer Can Have A Significant Emotional And Psychological Impact. It's Essential For Patients To Have Access To Counseling And Support Services.

• Support From Family And Friends Is Also Crucial During This Challenging Time.

Prevention and awareness

• Regular gynecological check-ups and screenings are vital for early detection.

• HPV vaccination is recommended to prevent HPV-related cancers, including vulva cancer.

• Women should be aware of their bodies and report any unusual symptoms promptly.

Survivorship and follow-up:

• After treatment, regular follow-up visits with healthcare providers are essential to monitor for any signs of recurrence.

• Many women with vulva cancer can lead healthy lives after successful treatment.

vulva cancer is a relatively rare but serious condition that primarily affects women. Early detection, prompt treatment, and ongoing awareness of risk factors are essential in improving outcomes and reducing the impact of this disease on individuals and their families. Education and open discussions about vulva cancer can help raise awareness and promote early intervention. The development of vulva cancer is a complex process that involves various genetic, environmental, and lifestyle factors. While the exact cause of vulva cancer is not always clear, several theories and risk factors have been proposed to help explain its origin and development:

HPV infection theory

• Human papillomavirus (HPV) infection is strongly associated with the development of vulva cancer. Certain high-risk strains of HPV, particularly HPV types 16 and 18, have been linked to an increased risk of vulva cancer.

• HPV infects the skin and mucous membranes of the genital area, leading to cellular changes that can progress to cancer over time. Immunosuppression:

• Women with weakened immune systems, whether due to medical conditions like HIV/AIDS or medications used after organ transplantation, have a higher risk of vulva cancer.

• A compromised immune system may struggle to control HPV infections and prevent the progression of precancerous lesions. Chronic inflammation and skin conditions:

• Chronic inflammatory conditions of the vulva, such as lichen sclerosus and lichen planus, have been associated with an increased risk of vulva cancer.

• Inflammation can damage DNA and promote cancerous changes in cells.

Smoking: Smoking tobacco is considered a risk factor for vulva cancer. The chemicals in tobacco smoke can be absorbed through the mucous membranes and skin, potentially contributing to the development of cancer.

Age: The risk of vulva cancer increases with age, with most cases diagnosed in women over the age of 65. Cellular changes and cumulative exposure to risk factors over time may contribute to this association.

Genetic factors: While most cases of vulva cancer are not directly linked to inherited genetic mutations, there may be genetic predispositions that make some individuals more susceptible to the disease. Studies are ongoing to explore the genetic aspects of vulva cancer.

Hormonal factors: Some research suggests that hormonal factors, such as estrogen exposure, may play a role in vulva cancer development. However, this area requires further investigation.

Personal hygiene and irritation: Practices that cause chronic irritation or inflammation in the vulvar area, such as the use of harsh soaps or excessive douching, have been theorized as potential contributors to vulva cancer. However, more research is needed in this area[3-8].

Conclusion

It's important to note that vulva cancer is a multifactorial disease, and not all individuals with these risk factors will develop the condition. Additionally, some cases of vulva cancer may occur without clear risk factors, emphasizing the need for ongoing research into its causes and prevention strategies. Preventive measures, such as HPV vaccination, smoking cessation, and regular gynaecological check-ups, can help reduce the risk of vulva cancer. Early detection through screenings and prompt medical attention for any concerning symptoms are essential for improving outcomes and increasing the chances of successful treatment.

1. Kunkle CM, Marchan J, Safadi S, Whitman S, Chmait RH (2015) Chlorhexidine gluconate versus povidone iodine at cesarean delivery: a randomized controlled trial. J Matern Fetal Neonatal Med 28: 573-577.

Indexed at, Google Scholar, Crossref

2. Rauk PN (2010) Educational intervention, revised instrument sterilization methods, and comprehensive preoperative skin preparation protocol reduce cesarean section surgical site infections. Am J Infect Control 38:319-323.

Indexed at, Google Scholar, Crossref

3. Darouiche RO, Wall MJ Jr, Itani KM, Otterson MF, Webb AL, et al. (2010) Chlorhexidine–alcohol versus povidone–iodine for surgical-site antisepsis. N Engl J Med 362:18-26.

Indexed at     Google Scholar, Crossref

4. Swenson BR, Hedrick TL, Metzger R, Bonatti H, Pruett TL, Sawyer RG (2009) Effects of preoperative skin preparation on postoperative wound infection rates: a prospective study of 3 skin preparation protocols. Infect Control Hosp Epidemiol 30:964-971.

Indexed at, Google Scholar, Crossref

5. Maiwald M, Chan ES (2012) The forgotten role of alcohol: a systematic review and meta-analysis of the clinical efficacy and perceived role of chlorhexidine in skin antisepsis. PLoS One 7: e44277.

Indexed at, Google Scholar, Crossref

6. Chuong EB, Hannibal RL, Green SL, Baker JC (2013) Evolutionary perspectives into placental biology and disease.Appl Transl Genom 2: 64-69.

Indexed at., Google Scholar  Crossref

7. Silver RM, Barbour KD (2015) Placenta accreta spectrum: accreta, increta, and percreta. Obstet Gynecol Clin North Am, 42: 381-402.

Indexed at, Google Scholar, Crossref

8. Bailit JL, Grobman WA, Rice MM, Reddy UM, Wapner RJ (2015) Morbidly adherent placenta treatments and outcomes. Obstet Gynecol 125: 683-689

Indexed at, Google Scholar, Crossref